Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM-201 versus recombinant human growth hormone in treatment-naive prepubertal children with idiopathic growth hormone deficiency
2020-000874-92Phase 2Completed
- Sponsor
- Lumos Pharma, Inc.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ibutamoren in idiopathic growth hormone deficiency (I-GHD) (4 arms), sponsored by Lumos Pharma, Inc. Primary endpoint: Preliminary clinical validation of predictive enrichment marker strategy. Started Oct 2020; status: completed.
02
Drugs
ibutamoren
03
Conditions
idiopathic growth hormone deficiency (I-GHD)
Beyond the preview
Go deeper on 2020-000874-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000874-92.